Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 403 (fulranumab) in healthy subjects
NCT02348879Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2005
- Primary completion
- Jan 2006
01
Overview
Phase 1, randomised, double-blind trial in chronic pain comparing AMG 403 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events at 112 days, Abnormal clinically significant vital signs at 112 days and 2 more. Started Jan 2005; status: completed.
02
Drugs
fulranumab
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT02348879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348879.